Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 02.06.2026 LANDXEN.LN IE000C75IMX8 15,878.00 USD 315,301.24 19.858  ...
-

LibertyStream Delivers First Tonne of Lithium Carbonate to U.S. Industrial Customer

DALLAS--(BUSINESS WIRE)--LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF | FSE: I2D) (“LibertyStream” or the “Company”) is pleased to announce that it has delivered its first tonne of lithium carbonate to a U.S. industrial customer from the Company’s DLE Unit and Lithium Carbonate Refining Facility at Select Water Solutions’ (NYSE: WTTR) (“Select”) site in Howard County, Texas, north of Midland. The delivery fulfills LibertyStream’s previously announced first U.S. order and...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 02.06.2026 LANDXN.LN IE000RN036E0 34,035.00 USD 740,834.75 21.767  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Innovative Transaction & Process UCITS ETF 02.06.2026 LEGR LN IE00BF5DXP42 950,002.00 USD 53,001,185.57 55.791  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NASDAQ Clean Edge Green Energy UCITS ETF 02.06.2026 QCLN.LN IE00BDBRT036 1,350,002.00 USD 35,708,105.33 26.450  ...
-

CoStar Data Shows Birmingham Posted Highest Retail Investment Volumes Since 2016

LONDON--(BUSINESS WIRE)--Shopping centre sales pushed Birmingham retail investments to a 10-year high, according to data from CoStar, a global leading provider of online real estate marketplaces, information and analytics in the property markets. The rolling 12-month average quarterly volume reached £202 million to the end of Q1, double the five-year annual average. “The pricing and scale of acquisitions reflect confidence in Birmingham’s position as a core retail destination, supported by stro...
-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trus...
-

GeoComply Expands Multi-Year Partnership with Caesars Entertainment

VANCOUVER, British Columbia--(BUSINESS WIRE)--GeoComply expands multi-year partnership with Caesars, deepening digital identity and fraud prevention across online gaming operations....
-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

Corrixr Therapeutics Names New CEO to Accelerate Momentum in Lead Program

NEWARK, Del.--(BUSINESS WIRE)--Corrixr Therapeutics, a pre-clinical genetic medicine company targeting lung, head & neck, and esophageal squamous cell carcinomas, today announced the appointment of Hilary M. Malone, Ph.D. as Chief Executive Officer. Dr. Malone brings more than 25 years of executive leadership experience across both multinational pharmaceutical companies and venture-backed biotech startups, combining deep expertise in science, regulatory strategy, clinical development, and p...